Axel B. Müller, managing director of Intergenerika, the Swiss generics association, reveals the penetration rate of generics in Switzerland; why generics are a safe, and smarter choice, manufactured to modern standards with affordable prices; and the threat of government forcing generic companies to benchmark their prices to nine European countries by 2017.
Can you give us an overview of the generics market in Switzerland today? Last year the market reached 637 million Francs (USD 648 million), seven percent growth in value over 2014, but market penetration still lags considerably behind the OECD average. Why is that?
The reason the generics market is not yet fully developed in Switzerland is in large part due to a lack of incentives for doctors and pharmacists when it comes to prescription
